A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study

Respir Med. 2016 Aug;117:223-9. doi: 10.1016/j.rmed.2016.06.017. Epub 2016 Jun 23.


Rationale: Long-term prognosis of adult-onset asthma is poorly known.

Objective: To evaluate 12-year prognosis of adult-onset asthma and the factors associated with disease prognosis.

Methods: Seinäjoki Adult-onset Asthma Study (SAAS) is a 12-year real-life single-center follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialized care. Remission was defined by no symptoms and no asthma medication use for 6 months. Asthma control was evaluated according to Global Initiative for Asthma 2010. Factors associated with current asthma control were analyzed by multinomial multivariate logistic regression.

Main results: A total of 203 patients (79% of the baseline population) were followed for 12 years. Remission occurred in 6 (3%) patients. In 34% asthma was controlled, in 36% it was partially controlled and in 30% uncontrolled. Uncontrolled asthma was predicted by elevated body-mass index at baseline, smoking (pack-years) and current allergic or persistent rhinitis. Elevated blood eosinophils and good lung function (FEV1) at baseline protected from uncontrolled asthma. In contrast, gender, age at the onset or baseline symptoms (Airways Questionnaire 20) were not significant predictors of uncontrolled disease.

Conclusions: During a 12-year follow-up, remission of adult-onset asthma was rare occurring in only 3% of patients. The majority of patients (66%) presented either with uncontrolled or partially controlled asthma. This study is registered at ClinicalTrials.gov with identifier number NCT02733016.

Keywords: Adult; Asthma; Control; Eosinophils; Follow-up; Remission.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset*
  • Aged
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / diagnosis*
  • Asthma / drug therapy
  • Asthma / epidemiology
  • Eosinophils / cytology
  • Eosinophils / physiology
  • Female
  • Follow-Up Studies
  • Forced Expiratory Volume / physiology
  • Humans
  • Male
  • Middle Aged
  • Prognosis*
  • Remission, Spontaneous
  • Rhinitis / epidemiology
  • Severity of Illness Index
  • Smoking / epidemiology


  • Anti-Asthmatic Agents

Associated data

  • ClinicalTrials.gov/NCT02733016